Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

The World Health Organization reports that around 2.2 billion people struggle with vision problems such as near-sightedness ...

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition.

“Good” HDL cholesterol appears to increase risk of glaucoma in people older than 55, researchers reported Feb. 4 in the ...

Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

What you need to know about the new video connection standards that were announced earlier this year at CES 2025.

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...